Skip to main content

Renovacor, Inc. (RCOR)

NYSE American Exchange Healthcare BiotechnologyView data quality →
26.3Poor

ValueMarkers Composite Index

Top 0%#44,702 of 44,707

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Renovacor, Inc. (RCOR) — VMCI valuation read

Renovacor, Inc. (RCOR) carries a VMCI composite of 26/100, 24 points below the Healthcare sector median of 50. Among mid-cap names, that gap places RCOR in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The RCOR insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads RCOR trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.4x is the rate-sensitivity line to watch, the line to track on Renovacor, Inc.'s next 10-Q.

RCOR rose 3.9% over the trailing 7 days, with a -23.3% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in RCOR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.